Entereg RiskMAP’s Ability To Prevent Heart Attacks Gets Advisory Panel Review
FDA questions the risk-management plan proposed by GlaxoSmithKline/Adolor to address myocardial infarctions reported in Phase III studies for alvimopan in GI indication.
FDA questions the risk-management plan proposed by GlaxoSmithKline/Adolor to address myocardial infarctions reported in Phase III studies for alvimopan in GI indication.